Bio-Hermes

Built on diversity

As GAP’s first-ever blood and digital biomarker platform study, Bio-Hermes enrolled more than 1,000 study volunteers:

24% percent from traditionally underrepresented communities — vastly surpassing the diversity rate of other clinical trials
400+ healthy, or without expressed problems with their memory or thinking
300+ with mild cognitive impairment
270+ with mild Alzheimer’s disease

Built on meaningful data

By providing head-to-head comparisons of data available from many leading Alzheimer’s diagnostic tests today, Bio-Hermes reduces historical barriers to access to timely diagnosis and care.

Bio-Hermes examines:

14 blood-based biomarkers: peripheral biomarkers
15 digital tests: speech analytics, computerized cognitive assessment using adaptive psychophysics, and digital remote brain health screenings
4 cognitive: retinal imaging, PET Central Reader, statistical analysis, and artificial intelligence

Built on collaboration

Part of Bio-Hermes’ success is in the impressive collaboration that brought together leading biopharma, technology and nonprofit partners and seventeen GAP-Net clinical research sites around the United States.

What comes next

The success of the Bio-Hermes study opens up the door for new research and diagnostics. This is especially true when data from Bio-Hermes becomes available to Alzheimer’s researchers worldwide as part of the Alzheimer’s Disease Discovery Initiative’s AD Workbench.

The study’s success in improving participation of participants who are traditionally underrepresented in clinical trials paves the way for future clinical research to represent the people who are most likely to develop Alzheimer’s and other neurodegenerative diseases.

Menu

Built on diversity

Built on meaningful data

Built on collaboration

What comes next

Thank you to our research & scientific partners